Article
Inhibiting an RBM39/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation.
Cell reports - 1 Jun 2021
Puvvula Pavan Kumar, Yu Yao, Sullivan Kaelan Renaldo, Eyob Henok, Rosenberg Julian, Welm Alana, Huff Chad, Moon Anne M
Abstract excerpt
RBM39 is a known splicing factor and coactivator. Here, we report that RBM39 functions as a master transcriptional regulator that interacts with the MLL1 complex to facilitate chromatin binding and H3K4 trimethylation in breast cancer cells. We identify RBM39 functional domains required for DNA and complex binding and show that the loss of RBM39 has widespread effects on H3K4me3 and gene expression, including key...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.